Chimeric antigen receptors: A cell and gene therapy perspective Journal Article


Authors: Rivière, I.; Sadelain, M.
Article Title: Chimeric antigen receptors: A cell and gene therapy perspective
Abstract: Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T lymphocytes to target chosen antigens. The targeting of CD19, a cell surface molecule expressed in the vast majority of leukemias and lymphomas, has been successfully translated in the clinic, earning CAR therapy a special distinction in the selection of “cancer immunotherapy” by Science as the breakthrough of the year in 2013. CD19 CAR therapy is predicated on advances in genetic engineering, T cell biology, tumor immunology, synthetic biology, target identification, cell manufacturing sciences, and regulatory compliance—the central tenets of CAR therapy. Here, we review two of these foundations: the genetic engineering approaches and cell types to engineer. © 2017 The American Society of Gene and Cell Therapy
Keywords: leukemia; review; nonhuman; t cells; t lymphocyte; cancer immunotherapy; protein targeting; acute lymphoblastic leukemia; rna; regulatory t lymphocyte; lymphocyte activation; dna; immunotherapy; genetic engineering; lymphoma; gene therapy; lentivirus vector; retrovirus vector; chimeric antigen receptor; cell therapy; pluripotent stem cell; lymphoid progenitor cell; cd19 antigen; transposon; tumor immunology; phase 1 clinical trial (topic); lymphocyte subpopulation; synthetic biology; vectors; cell engineering; car; human; genome editing; gene editing
Journal Title: Molecular Therapy
Volume: 25
Issue: 5
ISSN: 1525-0016
Publisher: Nature Publishing Group  
Date Published: 2017-05-03
Start Page: 1117
End Page: 1124
Language: English
DOI: 10.1016/j.ymthe.2017.03.034
PROVIDER: scopus
PMCID: PMC5417838
PUBMED: 28456379
DOI/URL:
Notes: Review -- Export Date: 1 December 2017 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Michel W J Sadelain
    583 Sadelain
  2. Isabelle C Riviere
    240 Riviere